Skip to content

Released Nov 15, 2021, after the close

10-Q filed Nov 15, 2021, 46 days after period end · 0001493152-21-028584

Q2 2022 · 10-Q
Revenue$8.56M+15.7% vs Q2 2021+21.3% vs Q1 2022
Net Income$1.80M−27.6% vs Q2 2021−24.8% vs Q1 2022
EPS Diluted$0.00— vs Q2 2021no prior Q1 2022 on file
Gross Profit$3,768,149+4.1%
Operating Income$1,422,577+6.1%
Operating Cash Flowderived$153,785−91.9%
Margins · derived
Gross margin44.0%−4.9 pt vs Q2 2021
Operating margin16.6%−1.5 pt vs Q2 2021
Net margin21.0%−12.5 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$8.56M$7.40M$4.63M$1.36M
Net Income$1.80M$2.48M-$1.60M-$2.58M
EPS Diluted$0.00$0.00$0.00$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR